Pomalidomide, bortezomib, and dexamethasone for patients with relapsed lenalidomide-refractory multiple myeloma
Jonas Paludo,Joseph R. Mikhael,Betsy LaPlant,Alese E. Halvorson,Shaji Kumar,Morie A. Gertz,Suzanne R. Hayman,Francis K. Buadi,Angela Dispenzieri,John A. Lust,Prashant Kapoor,Nelson Leung,Stephen J. Russell,David Dingli,Ronald S. Go,Yi Lin,Wilson I. Gonsalves,Rafael Fonseca,P. Leif Bergsagel,Vivek Roy,Taimur Sher,Asher Chanan-Khan,Sikander Ailawadhi,A. Keith Stewart,Craig B. Reeder,Paul G. Richardson,S. Vincent Rajkumar,Martha Q. Lacy +27 more
Reads0
Chats0
TLDR
PVD is a highly effective combination in lenalidomide-refractory MM patients and weekly administration of bortezomib enhanced tolerability and convenience, and toxicities are manageable.About:
This article is published in Blood.The article was published on 2014-12-06 and is currently open access. It has received 69 citations till now. The article focuses on the topics: Pomalidomide & Bortezomib.read more
Citations
More filters
Journal ArticleDOI
Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial
TL;DR: Pomalidomide, bortezomib, and dexamethasone significantly improved progression-free survival compared with bortzomib and patients with relapsed or refractory multiple myeloma, as assessed by an independent review committee.
Journal ArticleDOI
Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond
Chor S. Chim,Shaji Kumar,Robert Z. Orlowski,Gordon Cook,P. G. Richardson,Morie A. Gertz,Sergio Giralt,M.V. Mateos,Xavier Leleu,Kenneth Anderson +9 more
TL;DR: Clinical trial data of next generation proteasome inhibitors, next-generation immunomodulatory agent, and monoclonal antibodies approved for relapsed and refractory multiple myeloma are summarized, cautious interpretation of RCTs highlighted, and algorithm for salvage treatment of relapse/refractory MM proposed.
Journal ArticleDOI
The proteasome and proteasome inhibitors in multiple myeloma
Sara Gandolfi,Jacob P. Laubach,Teru Hideshima,Dharminder Chauhan,Kenneth C. Anderson,Paul G. Richardson +5 more
TL;DR: Proteasome inhibitor-based combination regimens have become established as a cornerstone of therapy throughout the myeloma treatment algorithm, incorporating agents from the other key classes of antimyeloma agents, including the immunomodulatory drugs, monoclonal antibodies, and histone deacetylase inhibitors.
Journal ArticleDOI
Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial.
Maria-Victoria Mateos,Hilary Blacklock,Fredrik Schjesvold,Albert Oriol,David Simpson,Anupkumar George,Hartmut Goldschmidt,Alessandra Larocca,Asher Chanan-Khan,Daniel W. Sherbenou,Irit Avivi,Noam Benyamini,Shinsuke Iida,Morio Matsumoto,Kenshi Suzuki,Vincent Ribrag,Saad Z. Usmani,Sundar Jagannath,Enrique M. Ocio,Paula Rodriguez-Otero,Jesús F. San Miguel,Uma Kher,Mohammed Z.H. Farooqui,Jason J. Z. Liao,Patricia Marinello,Sagar Lonial,Andrew Nicol,George Grigoriadis,John Catalano,Richard Leblanc,Mohamed Elemary,Nizar J. Bahlis,Thierry Facon,Lionel Karlin,Michel Attal,Monika Engelhardt,Katja Weisel,Andreas Mackensen,Arnon Nagler,Dina Ben Yehuda,Hila Magen-Nativ,Antonio Palumbo,Michele Cavo,Kensei Tobinai,Takaai Chou,Hiroshi Kosugi,Masafumi Taniwaki,Kazutaka Sunami,Kiyoshi Ando,Peter Ganly,Bjorn Gjertsen,Juan J. Lahuerta,Joan Bladé,Albert Oriol Rocafiguera,Maria V. Mateos,Maria V. Mateos,Sarah Larson,Djordje Atanackovic,Srinivas Devarakonda,Jacob D. Bitran,Jeffrey A. Zonder,Neil Morganstein,Mohammad Hay,Gene Saylors,Ebenezer Kio,Ira Oliff,Dean Kirkel,Mikhail Shtivelband,Carrie Yuen,Andrew Yee,Jatin P. Shah,Myo Htut,Shahzad Raza,Saurabh Chhabra,Patrick J. Stiff,Parameswaran Hari,Bruce Bank,Ehsan Malek,Cristina Gasparetto,Ycaoub Faroun,William Kreisle,Seema Singhal,Jacalyn Rosenblatt,Saad Usmani,Saad Usmani,Wes Lee,Hana Safah,Jose Lutzky,Jason Suh,Dorothy Pan,Ari Baron,Robert Manges,Ronald Steis,Moacyr Oliveira,Jan S. Moreb,Natalie S. Callander,Bertrand Anz,Anastasios Raptis,Laura Stampleman,Jason Melear,Thomas E. Boyd,Lawrence Garbo,Leonard Klein,Spencer Shao,Roger M. Lyons,Kristi McIntyre,Stefano R. Tarantolo,Christopher Yasenchak,Habte A. Yimer +108 more
TL;DR: The FDA established that risks associated with the triple combination outweighed benefits and halted the study and presented an unplanned, ad-hoc interim analysis.
Journal ArticleDOI
Immunomodulatory Drugs in Multiple Myeloma: Mechanisms of Action and Clinical Experience
TL;DR: The clinical efficacy of these agents in myeloma is reviewed and the structure-function relationship, the molecular mechanisms of action, and the association of IMiDs with second primary malignancies and thrombosis are discussed.
References
More filters
Journal ArticleDOI
Improved survival in multiple myeloma and the impact of novel therapies
Shaji Kumar,S. Vincent Rajkumar,Angela Dispenzieri,Martha Q. Lacy,Suzanne R. Hayman,Francis K. Buadi,Steven R. Zeldenrust,David Dingli,Stephen J. Russell,John A. Lust,Philip R. Greipp,Robert A. Kyle,Morie A. Gertz +12 more
TL;DR: Improved outcome of patients with myeloma in recent years is demonstrated, both in the relapsed setting as well as at diagnosis, both from time of diagnosis and the time of relapse.
Journal ArticleDOI
Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma
Antonio Palumbo,Asher Chanan-Khan,Katja Weisel,Ajay K. Nooka,Tamás Masszi,Meral Beksac,Ivan Spicka,Vania Hungria,Markus Munder,Maria-Victoria Mateos,Tomer M Mark,Ming Qi,Jordan M. Schecter,Himal Amin,Xiang Qin,William Deraedt,Tahamtan Ahmadi,Andrew Spencer,Pieter Sonneveld +18 more
TL;DR: Among patients with relapsed or relapsed and refractory multiple myeloma, daratumumab in combination with bortezomib and dexamethasone resulted in significantly longer progression-free survival than borteonib and DexamethAsone alone and was associated with infusion-related reactions and higher rates of thrombocytopenia and neutropenia.
Journal ArticleDOI
Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma
Meletios A. Dimopoulos,Albert Oriol,Hareth Nahi,Jesús F. San-Miguel,Nizar J. Bahlis,Saad Z. Usmani,Neil Rabin,Robert Z. Orlowski,Mieczysław Komarnicki,Kenshi Suzuki,Torben Plesner,Sung-Soo Yoon,Dina Ben Yehuda,Paul G. Richardson,Hartmut Goldschmidt,Hartmut Goldschmidt,Donna E. Reece,Steen Lisby,Nushmia Z. Khokhar,Lisa O'Rourke,Christopher Chiu,Xiang Qin,Mary E. Guckert,Tahamtan Ahmadi,Philippe Moreau +24 more
TL;DR: The addition of daratumumab to lenalidomide and dexamethasone significantly lengthened progression-free survival among patients with relapsed or refractory multiple myeloma.
Journal ArticleDOI
Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma
TL;DR: In patients with relapsed multiple myeloma, the addition of carfilzomib to lenalidomide and dexamethasone resulted in significantly improved progression-free survival at the interim analysis and had a favorable risk–benefit profile.
Journal ArticleDOI
Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma
Robert A. Kyle,S V Rajkumar +1 more
TL;DR: A new risk stratification model is provided to specifically define high-risk patients who may benefit from novel therapeutic strategies in multiple myeloma.
Related Papers (5)
Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma
Philippe Moreau,Tamás Masszi,Norbert Grzasko,Nizar J. Bahlis,Markus Hansson,Ludek Pour,Irwindeep Sandhu,Peter Ganly,Bartrum W Baker,Sharon Jackson,Anne-Marie Stoppa,D. Simpson,Peter Gimsing,Antonio Palumbo,Laurent Garderet,Michele Cavo,Shaji Kumar,Cyrille Touzeau,Francis K. Buadi,Jacob P. Laubach,Deborah Berg,J. Lin,Alessandra Di Bacco,Ai Min Hui,Helgi van de Velde,Paul G. Richardson +25 more
Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma
Abstr Act,Sagar Lonial,Meletios A. Dimopoulos,Antonio Palumbo,Darrell White,Sebastian Grosicki,Ivan Spicka,Adam Walter‑Croneck,Philippe Moreau,Maria-Victoria Mateos,Hila Magen,Andrew Belch,Donna E. Reece,Meral Beksac,Andrew Spencer,Heather Oakervee,Robert Z. Orlowski,Masafumi Taniwaki,Christoph Röllig,Hermann Einsele,Ka Lung Wu,Anil K. Singhal,Jesús F. San Miguel,Morio Matsumoto,Jessica Katz,Eric Bleickardt,Valerie Poulart,Kenneth C. Anderson,Paul G. Richardson +28 more
Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma
Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma
Meletios A. Dimopoulos,Albert Oriol,Hareth Nahi,Jesús F. San-Miguel,Nizar J. Bahlis,Saad Z. Usmani,Neil Rabin,Robert Z. Orlowski,Mieczysław Komarnicki,Kenshi Suzuki,Torben Plesner,Sung-Soo Yoon,Dina Ben Yehuda,Paul G. Richardson,Hartmut Goldschmidt,Hartmut Goldschmidt,Donna E. Reece,Steen Lisby,Nushmia Z. Khokhar,Lisa O'Rourke,Christopher Chiu,Xiang Qin,Mary E. Guckert,Tahamtan Ahmadi,Philippe Moreau +24 more